Can I Take Omega-3 (EPA/DHA) with Cytomel (Liothyronine)?

Direct answer

Liothyronine (brand name Cytomel), a synthetic, immediate-acting form of triiodothyronine (T3) used for hypothyroidism and occasionally myxedema coma, does not have a documented pharmacokinetic interaction with omega-3 fatty acids (eicosapentaenoic acid, EPA, and docosahexaenoic acid, DHA), whether from a standard fish-oil supplement or a prescription formulation such as icosapent ethyl (Vascepa) or omega-3-acid ethyl esters (Lovaza). No published evidence shows omega-3 changing liothyronine's gut absorption, its binding to thyroid-binding globulin, or its hepatic clearance at doses used in supplements or in prescription lipid management.

The overlap that matters is pharmacodynamic. Thyroid hormone and omega-3 fatty acids both lower triglycerides through separate mechanisms, and both have been associated with mild antiplatelet activity at higher exposures. For a patient on standard-dose liothyronine and a typical 1 to 2 g/day fish-oil supplement, this overlap is unlikely to be clinically meaningful. For a patient on prescription-dose omega-3 (3 to 4 g/day) or one who is also taking an anticoagulant or antiplatelet drug, the combination deserves a documented conversation with the prescriber rather than silent co-use.

The core claim, with its boundary

Liothyronine and omega-3 fatty acids do not interact at the level of drug absorption, protein binding, or metabolism at doses used in practice; the interaction that exists is pharmacodynamic, arising because both agents independently lower triglycerides and both have mild antiplatelet effects at higher doses. This pattern is supported by the separate pharmacology of each agent rather than by a dedicated trial of the combination, which does not appear to exist in the published literature. The practical consequence is that routine use of standard-dose omega-3 supplements alongside standard-dose liothyronine does not require special testing, while prescription-level omega-3 (3 to 4 g/day) combined with liothyronine, or either agent combined with an anticoagulant, warrants closer lipid and bleeding-risk follow-up.

Why there is no expected absorption problem

Several common supplements do interfere with thyroid hormone absorption. Calcium carbonate and iron taken close to levothyroxine (T4) are well documented to reduce its absorption, which is why patients are told to separate those products by several hours. Omega-3 fatty acids are structurally and chemically different from these mineral binders; they are not ionic chelators of thyroid hormone, and no published pharmacokinetic study has shown EPA or DHA altering liothyronine's absorption or clearance. Liothyronine also absorbs faster than levothyroxine and does not depend on gastric alkalinity to the same degree, which further reduces the theoretical plausibility of a gut-level conflict.

A separate, older theoretical concern is that high concentrations of free fatty acids could displace thyroid hormone from albumin, since both compete for the same binding sites. Laboratory work on this displacement effect has generally shown it requires free fatty acid concentrations far above what dietary or even prescription-dose omega-3 supplementation produces in the bloodstream. This is a plausible mechanism, not a documented clinical effect, and it should be described that way rather than as an established risk.

Where the real overlap sits: triglycerides and platelets

Triglycerides. Thyroid hormone (T3) upregulates hepatic LDL receptors and reduces circulating triglyceride-rich lipoproteins; this is a well-established physiological effect of thyroid status, which is one reason hypothyroid patients often have elevated triglycerides that improve with adequate treatment. Prescription-dose omega-3, particularly icosapent ethyl and omega-3-acid ethyl esters, has strong trial evidence for lowering triglycerides, and the American Heart Association's 2019 science advisory on omega-3 fatty acids for hypertriglyceridemia summarizes this evidence for clinicians (see AHA advisory). Two large cardiovascular outcomes trials illustrate that not all omega-3 formulations behave the same way: one pure-EPA formulation showed a cardiovascular benefit in high-risk patients with elevated triglycerides, while a separate EPA+DHA formulation lowered triglycerides without replicating that outcome benefit. The exact effect sizes from those trials are widely reported but are not reproduced here as numbers, because verifying the precise figures against the primary publications is an editorial step this draft has not completed; a reviewer should confirm specific percentages before they are quoted to a patient.

The practical implication for this page's audience: a patient who is newly euthyroid on liothyronine may already have falling triglycerides before omega-3 is added. Starting or increasing high-dose omega-3 at the same time can produce a triglyceride reduction larger than either agent would produce alone, which is not dangerous by itself but should be interpreted in context rather than assumed to reflect a new health problem.

Platelets and bleeding. Thyroid hormone increases turnover of coagulation factors, and hyperthyroid or high-normal free T3 states have been associated with reduced platelet aggregation in some studies. Omega-3 fatty acids inhibit the conversion of arachidonic acid to thromboxane A2 and reduce platelet aggregation in a dose-dependent way, an effect that becomes measurable at doses in the 3 to 4 g/day range. Neither effect is large enough on its own, in a patient without other bleeding risk factors, to produce clinically significant bleeding. The risk changes when the patient is also on warfarin, a direct oral anticoagulant, clopidogrel, or daily aspirin, or when a procedure is scheduled and the anesthesia and surgical teams have not been told about both agents.

What about thyroid autoimmunity and TSH?

Omega-3 fatty acids have anti-inflammatory properties, and some small trials in patients with Hashimoto thyroiditis have reported reductions in thyroid antibody titers with omega-3 supplementation. This line of evidence is preliminary. It has not been replicated in a large, powered trial, and it does not establish that omega-3 changes a patient's required liothyronine dose. Separately, observational data in people not on thyroid medication have suggested an association between higher habitual omega-3 intake and lower TSH, but an association in untreated adults does not tell us what happens in a patient already stabilized on liothyronine. Neither line of evidence should change a liothyronine dose without a follow-up TSH and free T3 confirming the change is real.

Evidence-status interaction assessment

This table distinguishes between effects supported by current research and those that are theoretically possible based on how liothyronine works in the body but lack clinical proof, while highlighting claims that require professional verification before being considered established.

Dose tiers and monitoring

The severity of the pharmacodynamic overlap tracks with omega-3 dose more than with any other single variable.

No specific timing separation between liothyronine and omega-3 is required. Liothyronine is often taken on an empty stomach per standard thyroid-medication instructions, and fish oil is commonly taken with food, so the two are usually separated by routine habit rather than by pharmacologic necessity.

What the primary literature search actually turned up

A dedicated clinical trial studying liothyronine and omega-3 fatty acids together as a primary endpoint does not appear to exist in the published literature. That is a gap in the evidence, not evidence of a hidden problem. A targeted search for primary literature on this specific pairing did not surface a controlled human study; the closest indexed research found was an unrelated animal study with no relevance to human thyroid hormone dosing or physiology, underscoring that no applicable evidence exists for this combination.

In the absence of a direct trial, this assessment relies on the separate, better-established pharmacology of each agent (thyroid hormone's effect on lipids and coagulation factors, and omega-3's effect on triglycerides and platelet function), combined with guideline-level statements on each agent individually. Anyone updating this page with specific effect sizes from named trials should verify those numbers against the original publications before publishing them, rather than relying on secondary summaries.

Special populations

Cardiovascular disease. Patients on prescription-dose omega-3 for hypertriglyceridemia who are also on liothyronine for hypothyroidism should have lipid panels reviewed on a schedule set by their cardiology or primary care team, since the combination could produce triglyceride levels low enough to complicate standard risk-calculator interpretation. Statin therapy remains the primary tool for LDL management in this group; this combination does not change statin indications.

Hashimoto thyroiditis on combination therapy. This group is likely to be using both agents already, given how commonly omega-3 supplements are used by people with autoimmune conditions. If antibody titers are already being tracked, continuing that alongside standard TSH monitoring gives the most complete picture, though no data currently show that omega-3-driven antibody changes reliably shift liothyronine dose requirements.

Pregnancy. The American College of Obstetricians and Gynecologists recommends omega-3 intake, including DHA, during pregnancy for fetal neurodevelopment (ACOG nutrition FAQ); patients should confirm the specific target amount with their obstetric provider rather than relying on a single figure here. Levothyroxine, not liothyronine, is the standard thyroid hormone replacement in pregnancy. If a patient is on liothyronine going into pregnancy under physician guidance, adding a prenatal omega-3 supplement does not introduce a new pharmacokinetic concern, but TSH and free T3 should be checked frequently in the first trimester regardless of omega-3 use, as is standard obstetric thyroid management.

Practical steps if you are already taking both

1. Tell your prescriber the exact omega-3 product and dose, including milligrams of EPA and DHA separately, not just "fish oil."
2. Confirm your most recent TSH and free T3 are within your target range.
3. Ask for a fasting lipid panel if you have not had one in the past year, especially if you are on a higher-dose omega-3 product.
4. If you take an anticoagulant or antiplatelet medication, or have surgery scheduled, disclose both agents to your prescriber and to the surgical or anesthesia team.
5. Do not adjust your liothyronine dose based on a self-observed change in triglycerides. A triglyceride drop after starting omega-3 does not mean your thyroid dose is too high, and dose changes should be guided by TSH and free T3, not by lipid numbers alone.

What is established, what is plausible, and what is not established

Established: Liothyronine and omega-3 fatty acids have no known pharmacokinetic interaction. Both independently lower triglycerides through separate, well-characterized mechanisms. Both have dose-related antiplatelet activity.

Plausible but unproven: That combined use meaningfully increases bleeding risk in a patient without other bleeding risk factors. That omega-3-driven antibody reduction in Hashimoto disease changes long-term liothyronine dose requirements. That very high-dose omega-3 has any detectable effect on liothyronine pharmacokinetics.

Not established: A dedicated human trial of this specific combination. A validated threshold at which combined triglyceride lowering becomes clinically important rather than just noticeable on a lipid panel. Whether the TSH-lowering association seen in thyroid-medication-free adults applies to people already stabilized on liothyronine.

Anyone with new symptoms, unexplained bruising, palpitations, unusual weight change, or heat intolerance while on this combination should contact their prescriber rather than attributing the change to a supplement interaction, since these symptoms can also reflect a change in thyroid status that needs its own workup.

This article has not yet received qualified medical review and should be treated as a draft pending that review. It does not provide individualized dosing or diagnosis. Anyone changing thyroid medication or high-dose supplement use should do so with their prescribing clinician, and anyone with unexplained bleeding, chest pain, palpitations, or severe symptoms should seek urgent care.